Solventum (NYSE:SOLV) Earns Outperform Rating from Analysts at Wedbush

Posted by George Bondi on May 15th, 2026

Stock analysts at Wedbush started coverage on shares of Solventum (NYSE:SOLV – Get Free Report) in a research note issued on Friday, Marketbeat.com reports. The firm set an “outperform” rating and a $94.00 price target on the stock. Wedbush’s price target suggests a potential upside of 26.35% from the stock’s previous close.

A number of other equities analysts have also weighed in on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Rothschild & Co Redburn started coverage on Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective on the stock. BTIG Research reiterated a “buy” rating and set a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Mizuho set a $100.00 target price on Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Finally, Wells Fargo & Company decreased their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $84.25.

View Our Latest Analysis on Solventum

Solventum Stock Down 0.0%

Shares of SOLV opened at $74.40 on Friday. The firm has a market cap of $12.88 billion, a P/E ratio of 9.12, a price-to-earnings-growth ratio of 1.15 and a beta of 0.59. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The firm’s 50-day simple moving average is $67.86 and its 200 day simple moving average is $74.57.

Solventum (NYSE:SOLV – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the business posted $1.34 earnings per share. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Insider Buying and Selling at Solventum

In related news, Director Amy Mcbride Wendell bought 1,475 shares of Solventum stock in a transaction dated Tuesday, March 10th. The shares were bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.24% of the company’s stock.

Institutional Investors Weigh In On Solventum

A number of large investors have recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Solventum by 59.0% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 9,265 shares of the company’s stock valued at $605,000 after buying an additional 3,437 shares during the period. Sei Investments Co. raised its position in shares of Solventum by 335.0% in the 1st quarter. Sei Investments Co. now owns 240,581 shares of the company’s stock valued at $15,711,000 after buying an additional 185,271 shares in the last quarter. Lido Advisors LLC lifted its holdings in shares of Solventum by 13.0% during the 1st quarter. Lido Advisors LLC now owns 8,922 shares of the company’s stock worth $583,000 after acquiring an additional 1,023 shares during the period. State of Wyoming lifted its holdings in shares of Solventum by 768.1% during the 1st quarter. State of Wyoming now owns 6,363 shares of the company’s stock worth $416,000 after acquiring an additional 5,630 shares during the period. Finally, Cetera Investment Advisers boosted its position in shares of Solventum by 5.0% during the 1st quarter. Cetera Investment Advisers now owns 45,739 shares of the company’s stock worth $2,987,000 after acquiring an additional 2,166 shares in the last quarter.

About Solventum

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.